While the goal is to reduce the cost burden on US patients, many in the industry are warning that there could be consequences ...
Gen2X enhances the RAIN RFID protocol with faster inventories, improved sensitivity/range, tighter read-zone confinement, and ...
Increasingly complex cell therapy modalities, including multi-edit knock-in/knockout designs, are accelerating adoption of ...
AbbVie received a Complete Response Letter (CRL) from the FDA for its Biologics License Application (BLA) for ...
The FDA has granted Compass Pathways with a rolling review for a New Drug Application (NDA) for its investigational ...
In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license ...
FDA is formalizing RWD as core evidence, enabling “single pivotal trial plus confirmatory evidence” approaches that may ...
The deal secures Lilly an in vivo gene therapy platform that could make CAR-T cell therapies accessible to a far broader ...
Regeneron reached an agreement with the U.S. government to link current and future drug prices to those in other developed ...
Eligibility now includes ages 1–7 years with stage 2 T1D, defined by multiple diabetes autoantibodies plus dysglycemia ...
IV fluids like normal saline, dextrose, and sterile water are the most systemically dangerous shortages on the list, as they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results